Higher-dose RT lowers risk of recurrence but does not improve survival for men with prostate cancer
Share

Results of a recent NRG Oncology study, NRG Oncology/RTOG 0126, show that high-dose radiotherapy did not improve survival for men with intermediate-risk prostate cancer but did improve biochemical control and rates of distant metastases, when compared to standard radiotherapy. Men who received higher-dose radiotherapy underwent fewer salvage therapies to control tumors that had grown larger or had spread to another body site; however, they also experienced more side effects than did men on the standard radiotherapy treatment arm. This information will be invaluable for doctors and patients when deciding the best treatment course. Research efforts on this study were led by the Study Chair, Jeff M. Michalski, MD, of the Siteman Cancer Center at the Washington University School of Medicine in St. Louis. This analysis was published in JAMA Oncology on March 15, 2018, and Dr. Michalski was recently interviewed by JAMA Oncology in a podcast regarding the publication.

NRG Oncology/RTOG 0126 is the first study of its kind large enough to examine whether improvement in cancer control from escalating radiotherapy dose could convert into longer overall survival rates for such patients. The trial analyzed 1,499 participants: 748 men were randomly assigned to the experimental radiotherapy arm to receive

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD